Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 1;48(2):208-214.
doi: 10.1097/j.jcrs.0000000000000733.

Transepithelial accelerated corneal crosslinking for keratoconus eyes with maximum keratometry values larger than 58 diopters

Ling Sun  1 , Jing Zhao, Xiaoyu Zhang, Yang Shen, Mi Tian, Xingtao Zhou
Affiliations

Transepithelial accelerated corneal crosslinking for keratoconus eyes with maximum keratometry values larger than 58 diopters

Ling Sun et al. J Cataract Refract Surg. .

Abstract

Purpose: To evaluate the safety and efficacy of transepithelial accelerated corneal crosslinking (CXL) for advanced keratoconus eyes with maximum keratometry (Kmax) values >58 diopters (D).

Setting: Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Shanghai, China.

Design: Prospective parallel control study.

Methods: 41 keratoconus eyes from 41 patients (mean age, 21.93 ± 5.48 years) who underwent transepithelial accelerated CXL were included prospectively. The enrolled eyes were divided into 2 groups according to their Kmax values (Group A, Kmax ≥58.0 D; Group B, Kmax <58.0 D). The examinations including assessment of uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), corneal topography, and corneal endothelial cell density count were conducted preoperatively, at 1 day, 1 month, 3 months, 6 months, and 1 year postoperatively.

Results: All 41 eyes finished 1 year follow-up. No statistical difference was noted between the mean UDVA and CDVA in both groups throughout the follow-up duration. At 1-year postoperative follow-up, the CDVA increased by ≥2 lines in 45% (9/20) and 28.6% (6/21) eyes in Groups A and B, respectively. The mean preoperative Kmax in Groups A and B were 62.51 ± 3.34 D and 49.98 ± 4.32 D, respectively, and that at postoperative 1-year follow-up were 61.94 ± 4.11 D and 50.24 ± 4.72 D, respectively. The Kmax values of 30% (6/20) eyes in Group A and 4.8% (1/21) eyes in Group B decreased by more than 1 D. Deduction of flat K, steep K, mean K, and Kmax showed no significant difference between the 2 groups at 1-year postoperative follow-up. Moreover, 20% (4/20) and 23.8% (5/21) of eyes in Groups A and B, respectively, showed progress at postoperative 1-year follow-up.

Conclusions: Transepithelial accelerated CXL can safely treat advanced keratoconus eyes with Kmax values ≥58.0 D with some extent of efficacy and has similar progressive rate as Kmax values <58.0 D.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Changes in Snellen lines (%) of UDVA (A) and CDVA (B) at 1-year postoperative follow-up in both groups.
Figure 2.
Figure 2.
Difference in ΔKmax between Groups A (Kmax ≥58 D) and B (Kmax <58 D) at each postoperative visit. ΔKmax is defined as the difference in Kmax preoperative and each postoperative follow-up.
Figure 3.
Figure 3.
Changes in Kmax (ΔKmax) for individual patients in Groups A (Kmax ≥58 D) and B (Kmax <58 D) at 1-year postoperative follow-up. ΔKmax is defined as the difference in Kmax preoperative and 1-year postoperative follow-up. Dashed lines indicate 1 D of change.
See this image and copyright information in PMC

References

    1. Tuft SJ, Moodaley LC, Gregory WM, Davison CR, Buckley RJ. Prognostic factors for the progression of keratoconus. Ophthalmology 1994;101:439–447 - PubMed
    1. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol 2003;135:620–627 - PubMed
    1. Saffarian L, Khakshoor H, Zarei-Ghanavati M, Esmaily H. Corneal crosslinking for keratoconus in Iranian patients: outcomes at 1 year following treatment. Middle East Afr J Ophthalmol 2010;17:365–368 - PMC - PubMed
    1. Vinciguerra R, Romano MR, Camesasca FI, Azzolini C, Trazza S, Morenghi E, Vinciguerra P. Corneal cross-linking as a treatment for keratoconus: four-year morphologic and clinical outcomes with respect to patient age. Ophthalmology 2013;120:908–916 - PubMed
    1. Koller T, Mrochen M, Seiler T. Complication and failure rates after corneal crosslinking. J Cataract Refract Surg 2009;35:1358–1362 - PubMed

Publication types